Armistice Capital’s NeuroSense Therapeutics NRSN Stock Holding History

Armistice Capital’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,584,000	Closed	-$1.77M	–	305
2024 Q2	$1.77M	Buy	+1,584,000	New	+$2.02M	0.02%	150
2023 Q4	–	Sell	-662,000	Closed	-$470K	–	343
2023 Q3	$470K	Sell	662,000 -604,000	-48%	-$633K	0.01%	170
2023 Q2	$1.89M	Buy	+1,266,000	New	+$2.22M	0.03%	148

Other funds holding NRSN

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Armistice Capital's NRSN Position: Q3 2024 in Review

Armistice Capital sold out of NeuroSense Therapeutics (NRSN) in Q3 2024, closing a stake of 1,584,000 shares — an estimated $1.77M sold.

Armistice Capital first reported a position in NRSN in Q2 2023 and held it in 3 quarters. The position peaked at $1.89M in Q2 2023. 7 funds tracked by Wall St. Rank hold NRSN as of Q3 2024.

Armistice Capital reported no remaining NeuroSense Therapeutics position as of Q3 2024 after selling out during the quarter.
Armistice Capital sold 1,584,000 NeuroSense Therapeutics shares in Q3 2024, an estimated $1.77M.
Armistice Capital first reported a position in NeuroSense Therapeutics in Q2 2023 and held it in 3 quarters.
Armistice Capital's NeuroSense Therapeutics position peaked at $1.89M in Q2 2023.
7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.